Pathogenesis of psoriasis in the "omic" era. Part II. Genetic, genomic and epigenetic changes in psoriasis

doi:10.5114/ada.2020.96243

Review

. 2020 Jun;37(3):283-298.

doi: 10.5114/ada.2020.96243. Epub 2020 Jul 14.

Pathogenesis of psoriasis in the "omic" era. Part II. Genetic, genomic and epigenetic changes in psoriasis

Bogusław Nedoszytko¹, Aneta Szczerkowska-Dobosz¹, Marta Stawczyk-Macieja¹, Agnieszka Owczarczyk-Saczonek², Adam Reich³, Joanna Bartosiñska⁴, Aleksandra Batycka-Baran⁵, Rafał Czajkowski⁶, Iwona T Dobrucki⁷, Lawrence W Dobrucki^{7

8

9

10}, Magdalena Górecka-Sokołowska⁶, Anna Janaszak-Jasiecka⁹, Leszek Kalinowski^{9

10

11}, Dorota Krasowska⁴, Dorota Purzycka-Bohdan¹, Adrianna Radulska¹², Edyta Reszka¹³, Dominik Samotij³, Marta Sobalska-Kwapis¹⁴, Andrzej Słominski¹⁵, Radomir Słominski¹⁶, Dominik Strapagiel¹⁴, Justyna Szczêch³, Michał Żmijewski¹⁷, Roman J Nowicki¹

Affiliations

¹ Chair and Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.
² Chair and Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.
³ Department of Dermatology, University of Rzeszow, Rzeszow, Poland.
⁴ Chair and Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
⁵ Chair and Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
⁶ Chair and Department of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
⁷ Beckman Institute for Advanced Science and Technology, Urbana, IL, USA.
⁸ Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL.
⁹ Department of Medical Laboratory Diagnostics, Medical University of Gdansk, Gdansk, Poland.
¹⁰ Biobanking and Biomolecular Resources Research Infrastructure Poland (BBMRI.PL), Gdansk, Poland.
¹¹ Gdansk University of Technology, Gdansk, Poland.
¹² Department of Pharmaceutical Biochemistry, Medical University of Gdansk, Gdansk, Poland.
¹³ Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, Lodz, Poland.
¹⁴ Biobank Laboratory, University of Lodz, Lodz, Poland.
¹⁵ Department of Dermatology University of Alabama at Birmingham, Birmingham, USA.
¹⁶ Department of Medicine and Microbiology, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, USA.
¹⁷ Department of Histology, Medical University of Gdansk, Gdansk, Poland.

PMID: 32774210
PMCID: PMC7394158
DOI: 10.5114/ada.2020.96243

Review

Pathogenesis of psoriasis in the "omic" era. Part II. Genetic, genomic and epigenetic changes in psoriasis

Bogusław Nedoszytko et al. Postepy Dermatol Alergol. 2020 Jun.

. 2020 Jun;37(3):283-298.

doi: 10.5114/ada.2020.96243. Epub 2020 Jul 14.

Authors

Affiliations

¹ Chair and Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.
² Chair and Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.
³ Department of Dermatology, University of Rzeszow, Rzeszow, Poland.
⁴ Chair and Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
⁵ Chair and Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
⁶ Chair and Department of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
⁷ Beckman Institute for Advanced Science and Technology, Urbana, IL, USA.
⁸ Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL.
⁹ Department of Medical Laboratory Diagnostics, Medical University of Gdansk, Gdansk, Poland.
¹⁰ Biobanking and Biomolecular Resources Research Infrastructure Poland (BBMRI.PL), Gdansk, Poland.
¹¹ Gdansk University of Technology, Gdansk, Poland.
¹² Department of Pharmaceutical Biochemistry, Medical University of Gdansk, Gdansk, Poland.
¹³ Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, Lodz, Poland.
¹⁴ Biobank Laboratory, University of Lodz, Lodz, Poland.
¹⁵ Department of Dermatology University of Alabama at Birmingham, Birmingham, USA.
¹⁶ Department of Medicine and Microbiology, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, USA.
¹⁷ Department of Histology, Medical University of Gdansk, Gdansk, Poland.

PMID: 32774210
PMCID: PMC7394158
DOI: 10.5114/ada.2020.96243

Abstract

Psoriasis is a multifactorial disease in which genetic, environmental and epigenetic factors regulating gene expression play a key role. In the "genomic era", genome-wide association studies together with target genotyping platforms performed in different ethnic populations have found more than 50 genetic susceptible markers associated with the risk of psoriasis which have been identified so far. Up till now, the strongest association with the risk of the disease has been proved for HLA-C*06 gene. The majority of other psoriasis risk SNPs are situated near the genes encoding molecules involved in adaptive and innate immunity, and skin barrier function. Many contemporary studies indicate that the epigenetic changes: histone modification, promoter methylations, long non-coding and micro-RNA hyperexpression are considered as factors contributing to psoriasis pathogenesis as they regulate abnormal keratinocyte differentiation and proliferation, aberrant keratinocytes - inflammatory cells communication, neoangiogenesis and chronic inflammation. The circulating miRNAs detected in the blood may become specific markers in the diagnosis, prognosis and response to the treatment of the disease. The inhibition of expression in selected miRNAs may be a new promising therapy option for patients with psoriasis.

Keywords: epigenetic changes; genome-wide association studies; miRNA; psoriasis genetics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Scheme of the gene map of the MHC and the PSORS1 region on chromosome 6p21.3

**Figure 2**
Epigenetic modifications of DNA and histones in the development of different set of CD4 (+) T cells (from Potaczek *et al*. 2017 modified [70])

**Figure 3**
The role of selected mi-RNAs in regulation CD4(+) Th cells differentiation and cytokines synthesis

See this image and copyright information in PMC

Cited by

Analysis of selected genetic variants in psoriasis susceptibility and response to treatment.
Malinowski D, Białecka M, Bojko P, Kiszkielis A, Droździk M, Kurzawski M. Malinowski D, et al. Postepy Dermatol Alergol. 2022 Oct;39(5):934-939. doi: 10.5114/ada.2022.120885. Epub 2022 Nov 9. Postepy Dermatol Alergol. 2022. PMID: 36457676 Free PMC article.
Current Concepts of Psoriasis Immunopathogenesis.
Vičić M, Kaštelan M, Brajac I, Sotošek V, Massari LP. Vičić M, et al. Int J Mol Sci. 2021 Oct 26;22(21):11574. doi: 10.3390/ijms222111574. Int J Mol Sci. 2021. PMID: 34769005 Free PMC article. Review.
Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.
Luengas-Martinez A, Paus R, Young HS. Luengas-Martinez A, et al. Br J Dermatol. 2022 May;186(5):782-791. doi: 10.1111/bjd.20940. Epub 2022 Mar 17. Br J Dermatol. 2022. PMID: 34878645 Free PMC article. Review.
The Effects of Vitamin D on the Expression of IL-33 and Its Receptor ST2 in Skin Cells; Potential Implication for Psoriasis.
Wierzbicka JM, Piotrowska A, Purzycka-Bohdan D, Olszewska A, Nowak JI, Szczerkowska-Dobosz A, Nedoszytko B, Nowicki RJ, Żmijewski MA. Wierzbicka JM, et al. Int J Mol Sci. 2021 Nov 29;22(23):12907. doi: 10.3390/ijms222312907. Int J Mol Sci. 2021. PMID: 34884710 Free PMC article.
Association between United States Environmental Contaminants and the Prevalence of Psoriasis Derived from the National Health and Nutrition Examination Survey.
Guo L, Tu B, Li D, Zhi L, Zhang Y, Xiao H, Li W, Xu X. Guo L, et al. Toxics. 2024 Jul 19;12(7):522. doi: 10.3390/toxics12070522. Toxics. 2024. PMID: 39058174 Free PMC article.

See all "Cited by" articles

References

1. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;194:207–11. - PubMed
1. Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med. 1972;287:738–40. - PubMed
1. White SH, Newcomer VD, Mickey MR, et al. Disturbance of HL-A antigen frequency in psoriasis. N Engl J Med. 1972;287:740–3. - PubMed
1. Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143:1177–82. - PubMed
1. Gudjonsson JE, Karason A, Antonsdottir A, et al. Psoriasis patients who are homozygous for the Hla-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003;148:233–5. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;194:207–11. - PubMed

[2] Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;194:207–11. - PubMed

[3] Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med. 1972;287:738–40. - PubMed

[4] Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med. 1972;287:738–40. - PubMed

[5] White SH, Newcomer VD, Mickey MR, et al. Disturbance of HL-A antigen frequency in psoriasis. N Engl J Med. 1972;287:740–3. - PubMed

[6] White SH, Newcomer VD, Mickey MR, et al. Disturbance of HL-A antigen frequency in psoriasis. N Engl J Med. 1972;287:740–3. - PubMed

[7] Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143:1177–82. - PubMed

[8] Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143:1177–82. - PubMed

[9] Gudjonsson JE, Karason A, Antonsdottir A, et al. Psoriasis patients who are homozygous for the Hla-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003;148:233–5. - PubMed

[10] Gudjonsson JE, Karason A, Antonsdottir A, et al. Psoriasis patients who are homozygous for the Hla-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003;148:233–5. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pathogenesis of psoriasis in the "omic" era. Part II. Genetic, genomic and epigenetic changes in psoriasis

Affiliations

Pathogenesis of psoriasis in the "omic" era. Part II. Genetic, genomic and epigenetic changes in psoriasis

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Research Materials

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources

Research Materials